Dr. Fiona Lovegrove reports live from the 2023 EADV Congress in Berlin and discusses the late breaking presentation on rezpegaldesleukin.
EADV 2023 Day 3 Morning: Bullous Diseases
Dr. Fiona Lovegrove reports live from the 2023 EADV Congress in Berlin and gives insights into bullous diseases.
EADV 2023 Day 3 Evening: Molecular Signature of Chronic Hand Eczema
Dr. Vimal Prajapati reports live from the 2023 EADV Congress in Berlin and discusses the common molecular signature of chronic hand eczema.
EADV 2023 Day 2 Afternoon: Treating Severe Atopic Dermatitis with Tapinarof 1% Cream
Dr. Vimal Prajapati reports live from the 2023 EADV Congress in Berlin and discusses tapinarof 1% cream for treating severe atopic dermatitis
EADV 2023 Day 2 Morning: Late Breaking Psoriasis Presentations
Dr. Vimal Prajapati reports live from the 2023 EADV Congress in Berlin and discusses late breaker presentations around orally administered treatments for psoriasis
EADV 2023 Day 1 Evening: Late Breakers in Atopic Dermatitis
Dr. Mark Kirchhof reports live from the 2023 EADV Congress in Berlin and discusses late breaker presentations around atopic dermatitis and prurigo nodularis.
EADV 2023 Day 1 Afternoon: Late Breaking HS and Alopecia Developments
Dr. Mark Kirchhof reports live from the 2023 EADV Congress in Berlin and discusses the late breaker presentations about hidradenitis suppurativa and alopecia areata.
EADV 2023 Day 1 Morning: The Pathogenesis of Psoriasis
Dr. Mark Kirchhof reports live from the 2023 EADV Congress in Berlin and gives insights into the International Psoriasis Council presentations regarding the pathogenesis of psoriasis.
Dupilumab lowers IgE levels in AD patients regardless of dosing interval
According to a recent study, dupilumab successfully decreases immunoglobulin E (IgE) serum levels in atopic dermatitis (AD) patients regardless of dosing interval.
Study shows risankizumab is effective regardless of prior biologic treatment
According to a recent study, risankizumab is effective at achieving skin clearance in moderate-to-severe plaque psoriasis patients regardless of whether they have been treated with biologics previously.
HealthMinute.TV 